Clinical evaluation of the novel, UNI-directional, PD-103 civasheet for lung cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA217587
- Recipient
-
Civatech Oncology, Inc. UEI NCJMMLLMRND9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,925,953
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding
-
- $2,705,539.79 Federal
- $220,413.00 Non-federal
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$227 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $220,413 | $0 | |
| Amendment | $220,413 | $220,413 | |
| Amendment | $595 | $0 | |
| Amendment | $801,730 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,165,750 | $0 | |
| Original award | $296,866 | $0 |
Quick answers
Who received award R44CA217587?
R44CA217587 was awarded to Civatech Oncology, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2017.
How much is award R44CA217587 worth?
$2,925,953 has been obligated on R44CA217587: $2,705,540 in federal funding and $220,413 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award